Curriculum vitae

Curriculum vitae
Doeblinger Hauptstr.62/14, A-1190 Vienna, Austria, Tel.: 0676 760 6740
Current position:
Tenured Professor of Medicine,School of Medicine, University of Vienna, Department of Internal Medicine I, Division of Hematology and Hamostaseology, 1090 Vienna, Waehringer Guertel 18- 20, Austria. President of the Austrian Society of Oncological Rehabilitation and Psychooncology Education/Training:
University of Vienna, Austria Fellowship University of Vienna, Austria Board Exam 1995 University of Vienna, Austria Senior Attending Staff, on faculty 1995-present University of Vienna, Austria Specialization 1997 Hematology/Oncology University of Washington,USA Specialization 1998 Immunology/Oncology University of Vienna, Austria tenured Professor of Medicine 2002 Professional Experience:
Research Assistant University of Vienna, School of Medicine, Post-doctoral Fellowship, Department of Laboratory Medicine, Division of Molecular Biology, University of Vienna, Medical Fellow, First Dept. of Internal Medicine, University of Vienna. Research work on bcr-abl gene expression in CML Faculty Appointment: Senior Attending Staff, Univ.of Vienna Visiting Scientist, Senior Fellow, Division of Oncology, Chair Hematology Research, Senior Scientist, Corixa Corp, Seattle, USA. 1.Development of WT1 cancer vaccine. 2. Decoding the genome of hematological malignancies. 2003–present Head hematology outpatient unit, Director Lymphoma, CLL, Grants and Awards:
Fellowship Award of Excellence of the University of Vienna, Fellowship Award of Excellence of the University of Vienna Wilhelm Türk Award of the Austrian and German Wilhelm Türk Award of the Austrian and German Society Scientific Award for Pediatric Hematology and Oncology of the Austrian Committee of the Children Cancer

1. Over 100 patent publications 2. Full papers Prognostic value of T-cell receptor gamma rearrangement in peripheral blood
or bone marrow of patients with peripheral T-cell lymphomas.
Leuk Lymphoma. 2008 Feb;49(2):237-46.
Expression of MUM1/IRF4 mRNA as a prognostic
marker in patients with multiple myeloma.
Leukemia. 2007 Aug 9
Overexpression of
the paternally expressed gene 10 (PEG10) from the imprinted locus on chromosome 7q21
in high-risk B-cell chronic lymphocytic leukemia.
Int J Cancer. 2007 Nov 1;121(9):1984-93.
Autoimmune hemolytic anemias, Evans' syndromes, and pure red cell aplasia in non-
Hodgkin lymphomas. Leuk Lymphoma. 2007 Jun;48(6):1139-49. Review.
Clinical study on the effect of infrared radiation of a tiled stove on patients with hand
osteoarthritis. Scand J Rheumatol. 2006 Nov-Dec;35(6):476-80.
Upregulation of retinoic acid receptor-beta by the epidermal growth factor-
receptor inhibitor PD153035 is not mediated by blockade of ErbB pathways.
J Cell Physiol. 2007 Jun;211(3):803-15.
Influence of rituximab, cyclophosphamide, doxorubicin, vincristine and
prednisone on serologic parameters and clinical course in lymphoma patients with
autoimmune diseases. Ann Oncol. 2007 Apr;18(4):647-51. Epub 2007 Jan 11.
Assessment of
disease dissemination in gastric compared with extragastric mucosa-associated lymphoid
tissue lymphoma using extensive staging: a single-center experience. J Clin Oncol. 2006
Jul 1;24(19):3136-41. Epub 2006 Jun 12.
Deregulated expression of fat and muscle genes in B-cell
chronic lymphocytic leukemia with high lipoprotein lipase expression. Leukemia. 2006
Phase II study of oxaliplatin for treatment of patients
with mucosa-associated lymphoid tissue lymphoma.
J Clin Oncol. 2005 Nov 20;23(33):8442-6.
Remission of pure red cell aplasia in T-
cell receptor gammadelta-large granular lymphocyte leukemia after therapy with low-dose
Leukemia. 2005 Nov;19(11):2005-8. No abstract available.
Limited value of FLT3 mRNA expression in the bone marrow for prognosis and
monitoring of patients with acute myeloid leukemia.
Haematologica. 2005 May;90(5):695-6.
Wilms' tumour gene 1 (WT1) in human neoplasia.
Leukemia. 2005 Aug;19(8):1318-23.
High expression of lipoprotein lipase in poor
risk B-cell chronic lymphocytic leukemia. Leukemia. 2005 Jul;19(7):1216-23.
An EGF receptor inhibitor induces
RAR-beta expression in breast and ovarian cancer cells. Biochem Biophys Res Commun.
2005 Apr 22;329(4):1253-9.
Gaiger A, Heintel D, Jäger U. Novel molecular diagnostic and therapeutic targets in
chronic lymphocytic leukaemia. Eur J Clin Invest. 2004 Aug;34 Suppl 2:25-30. Review.
High expression of activation-induced cytidine deaminase (AID)
mRNA is associated with unmutated IGVH gene status and unfavourable cytogenetic
aberrations in patients with chronic lymphocytic leukaemia. Leukemia. 2004
Diamond DL, Zhang Y, Gaiger A, Smithgall M, Vedvick TS, Carter DUse of ProteinChip array surface enhanced laser desorption/ionization time-of-flight mass
spectrometry (SELDI-TOF MS) to identify thymosin beta-4, a differentially secreted
protein from lymphoblastoid cell lines. J Am Soc Mass Spectrom. 2003 Jul;14(7):760-5.
WT1 in acute leukemia, chronic myelogenous
leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies.
Leukemia. 2003 Jul;17(7):1301-12. Review.
Gaiger AWT1-specific serum antibodies in patients with
leukemia. Clin Cancer Res. 2001 Mar;7(3 Suppl):761s-765s.
Gaiger AImmunity to WT1 in the animal model and in
patients with acute myeloid leukemia. Blood. 2000 Aug 15;96(4):1480-9.
Gaiger AWilms' tumour gene (wt1) expression at diagnosis has no prognostic relevance in
childhood acute lymphoblastic leukaemia treated by an intensive chemotherapy protocol.
Eur J Haematol. 1999 Aug;63(2):86-93.
Immunophenotypic characterization of human bone marrow endosteal cells.
Tissue Antigens. 1999 Jun;53(6):559-68.
Telomere length shortening is associated with
disease evolution in chronic myelogenous leukemia.
Am J Hematol. 1999 May;61(1):5-9.
Gaiger ADetection of the WT1 transcript by RT-PCR in complete remission has no
prognostic relevance in de novo acute myeloid leukemia.
Leukemia. 1998 Dec;12(12):1886-94.
Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute
myeloid leukemia. Leukemia. 1997 May;11(5):639-43.
Amplification of mitochondrial DNA in acute
myeloid leukaemia. Br J Haematol. 1996 Nov;95(2):426-31.
Gaiger A,Increase of bcr-abl chimeric mRNA
expression in tumor cells of patients with chronic myeloid leukemia precedes disease
progression. Blood. 1995 Sep 15;86(6):2371-8.
Use of quantitative
polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia
during treatment with interferon. Leukemia. 1995 Aug;9(8):1353-60.
PCR-monitoring of minimal residual leukaemia
after conventional chemotherapy and bone marrow transplantation in BCR-ABL-positive
acute lymphoblastic leukaemia. Br J Haematol. 1995 Apr;89(4):937-41. Erratum in: Br J
Haematol 1995 Jun;90(2):492.
Absence of N-ras
mutations in myeloid and lymphoid blast crisis of chronic myeloid leukemia. Cancer Res.
1994 Jul 15;54(14):3934-8.
Gaiger AHLA class-I and -II antigens in
chronic idiopathic autoimmune thrombocytopenia. Ann Hematol. 1994 Jun;68(6):299-
Gaiger A, Frequent detection of BCR-ABL specific mRNA in
patients with chronic myeloid leukemia (CML) following allogeneic and syngeneic bone
marrow transplantation (BMT). Leukemia. 1993 Nov;7(11):1766-72.
Studies on oral contraceptive-induced changes in blood coagulation and fibrinolysis and
the estrogen effect on endothelial cells. Ann Hematol. 1993 Jul;67(1):33-6.
Early detection of relapse after bone
marrow transplantation in patients with chronic myelogenous leukaemia. Lancet. 1993 Jan
Monitoring of residual disease in
chronic myelogenous leukemia by quantitative polymerase chain reaction. Leukemia. 1992
[Problems of long-term
therapy with anticoagulants] Acta Med Austriaca. 1992;19(1):21-4. Review. German.
Pure red cell aplasia in a case
of Ph negative BCR/ABL rearranged CML with t(12;14)(q23;p11). Cancer Genet
Cytogenet. 1991 Oct 15;56(2):189-95.
Gaiger ADetection of engraftment and mixed chimerism following bone marrow
transplantation using PCR amplification of a highly variable region-variable number of
tandem repeats (VNTR) in the von Willebrand factor gene.
Ann Hematol. 1991 Oct;63(4):227-8.
Gaiger A[Chronic myeloid leukemia]
Wien Med Wochenschr. 1991;141(9-10):195-8. Review. German.


MATERIAL SAFETY DATA SHEETVEDCO TETRACYCLINE SOLUBLE POWDER 5OZ------------------------------------------------------------------------SECTION 1 - PRODUCT INFORMATION------------------------------------------------------------------------Manufacturer: Phoenix Scientific Inc. Address: Emergency Phone: (816) 364-3777 or (816) 253-9341 Trade Name: N/aChemical Name And Synonyms: Tetracycline Hydrochl 50 prods & description

Personal Care Skin Care □ Anti-perspirant & Deodorant Roll-on □ Anti-perspirant & Deodorant Spray □ Natural exfolient & fine line reduction Healthy Snacks & Drinks Health & Nutrition Household Cleaning T O P 5 0 D e s c r i p t i o n Personal Care LOC Plus Bathroom Cleaner (202600) Satinique Gentle Daily Cleanser (202388) Spray Bot

Copyright © 2008-2018 All About Drugs